

ANNUAL DECLARATION OF INTERESTS (ADoI)

(Please note that high quality of scientific expertise is by nature based on prior experience and that therefore having an interest does not necessarily mean having a conflict of interest)

Name: WRIGHT, Matthew

Title: Prof

Profession: Biochemistry

Current EFSA involvements: Member-FAF Panel 2018-2024 (FAF), Chair-FAF WG on Titanium dioxide (E171) (FAF), Member-WG on Sweeteners (FAF), Member-WG on the re-evaluation of remaining food additives other than colours and sweeteners (FAF)

| Nature of Activities | Period | Organisation | Subject matter |
|--|---------------|---|---|
| I. Financial investments | | | NO INTEREST |
| II. Managerial role | | | NO INTEREST |
| III. Member of a scientific advisory entity | 04/2017 - now | -Name: COT, Food Safety Agency Committee on Toxicity, COT, UNITED KINGDOM, London | Ordinary member of the committee. Role is advisory and does not include performance of risk management tasks. Impact on annual earnings: >0% and <5% |

| | | | |
|----------------------------------|-------------------|---|--|
| IV. Employment | 10/2006 - now | -Name: Newcastle University | <p>Main employment - Teaching/research in Toxicology. My research is on the PXR in inflammatory diseases, such as primary biliary cirrhosis; the development of human hepatocytes for toxicological research (toxicology and drug metabolism studies); investigations into xenoestrogens and cholestatic liver disease. I have significant experience of developing and running undergraduate courses and make contributions to Pharmacology and Toxicology teaching at undergraduate level. I also make a significant contributions to and at postgraduate teaching. I also undertake third strand activity through the continued development of a recombinant human antibody protein to a surface protein on fibrogenic cells.</p> <p>Impact on annual earnings: >25%</p> |
| V. Occasional consultancy | | | NO INTEREST |
| VI. Research funding | 09/2020 - 09/2023 | -Name: Newton Mosharafa Fund | PhD Studentship. Carboxylic acid drugs and chemicals – investigating their potential to trigger idiosyncratic liver injury and an auto-immune liver disease. |
| | 10/2018 - 09/2021 | -Name: Newcastle University Sustainability studentships | Can synergistic interactions between environmental toxins and high consumption of vitamins increase the risk to both animal and human health? |
| | 01/2014 - 12/2020 | -Name: NIHR | Health Protection Research Unit – theme lead for “Chemical Exposures and the Development of Primary Biliary Cirrhosis |
| | 04/2019 - 05/2020 | -Name: LIVERnORTH | Establishing a platform for the isolation of liver cells for liver disease research. |
| | 10/2015 - 04/2020 | -Name: National Institute of Health Research UK | BTRU Organ Donation and transplantation |
| | 12/2016 - 12/2019 | -Name: GlaxoSmithKline (GSK) | <p>Translation package for fibrosis imaging. The C-13 human antibody fragment was developed by my laboratory (see Elrick LJ, Leel V, Blaylock MG, Duncan L, Drever MR, Strachan G, Charlton KA, Koruth M, Porter AJ, Wright MC. Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells - a potential mechanism for targeting liver anti-fibrotic therapeutics. Journal of Hepatology 42, 888-896 (2005) / Douglass A, Wallace K, Park J, Parr R, Durward E, Broadbent I, Barelle C, Porter AJ, Wright MC. Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. Journal of Hepatology 49, 88-98 (2008)) and has recently been demonstrated to show promise as an imaging agent in animal models of liver fibrosis (Luli S, Di Paolo D, Perri P, Brignole C, Hill SJ, Brown H, Leslie J, Wright MC, Mann DA, Ponzoni M, Oakley F. A new fluorescence based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo. Journal of Hepatology 65, 75 - 83 (2016). The project seeks to build on these studies with a view to developing antibodies for clinical use.</p> |
| | 06/2019 - 08/2019 | -Name: British Toxicology Society | Vacation studentship. Drugs and chemical triggers of the liver auto-immune disease PBC |
| | 05/2019 - 07/2019 | -Name: Lubrizol | Toxicity of engine oils |
| | 12/2015 - 09/2018 | -Name: NC3Rs UK | 3D hiPSC derived Skin Metabolism Model |
| | 06/2014 - 06/2018 | -Name: Royal Embassy of Saudi Arabia | Potentiating stem cell-derived hepatocyte function - PhD studentship |
| | 01/2015 - 12/2017 | -Name: Gates Foundation | Assessing the risk of vitamin A toxicity due to large scale food fortification and other interventions |

| | | | |
|--|-------------------|---|---|
| | 01/2015 - 09/2017 | -Name: Iraq Government | Epigenetic regulation of gene expression and its role in the trans-differentiation of B-13 cells into functional hepatocytes - PhD studentship |
| | 10/2014 - 09/2017 | -Name: National Institute for Health Research UK | Rare Disease TRC The environmental and spatio-temporal epidemiology and environmental toxicology of rare autoimmune |
| | 01/2015 - 12/2016 | -Name: The European Foundation for Alcohol Research | Research project - The effect of alcohol on the absorption and toxicity of food chemicals via the gut |
| | 08/2012 - 09/2016 | -Name: Medical Research Council | ITTP studentship. Investigating the Adverse Effects of Novel Tumour-specific IAP Antagonists. |
| | 08/2012 - 09/2016 | -Name: Medical Research Council | Derivation of Human Hepatocytes from Pancreatic Progenitor Cells and their use in a Novel Antioxidant Screening Platform |
| | 08/2012 - 09/2016 | -Name: Medical Research Council | Targeting MEK and VEGF inhibition to prevent melanoma metastasis and angiogenesis. |
| | 12/2015 - 06/2016 | -Name: Wellcome Trust | Wellcome Trust Institutional Strategic Support Fund Project – Lipid peroxidation product profiles in acute ischaemia reperfusion injury |
| | 07/2015 - 06/2016 | -Name: LiverNorth Charity | Environmental chemicals, mitochondrial toxicity and triggers for PBC |
| | 10/2011 - 09/2015 | -Name: European Commission | Information and Communication Technology (ICT)-enabled, cellular artificial liver system incorporating personalised patient management and support (D-LIVER). |
| | 08/2014 - 08/2015 | -Name: Medical Research Council | A novel target to reduce graft failure in liver transplantation |
| | 08/2014 - 07/2015 | -Name: University of Newcastle upon Tyne, UNITED KINGDOM, Newcastle upon Tyne | Nature and Nurture: Linking causative agents in the environment with increased incidence of primary biliary cirrhosis. |
| VII. Intellectual property rights | 10/2007 - now | -Name: Pfizer | Previous employer (University of Aberdeen) IP protecting C1-3 antibody technology. I could receive personal financial benefit if the antibody is developed for use as a therapeutic in man. Impact on annual earnings: 0% |
| VIII. Other memberships or affiliations | 03/2019 - now | -Name: US SOT (Society of Toxicology) | Professional Society Impact on annual earnings: 0% |
| | 12/2000 - now | -Name: British Toxicology Society | Member Impact on annual earnings: 0% |
| | 10/1992 - 09/2016 | -Name: Biochemical Society | Member Impact on annual earnings: 0% |
| | 06/2013 - 06/2015 | -Name: In Vitro Toxicology Society | Member Impact on annual earnings: 0% |
| IX. Other relevant interest | 01/2018 - 12/2021 | -Name: ELSEVIER | Associate Editor for the journal Toxicology Impact on annual earnings: >0% and <5% |
| X. Interests of close family members | | | NO INTEREST |

I hereby declare that I have read both the Guidance Document on Declarations of Interests and the Procedure for identifying and handling potential conflict of interests and that the above Declaration of Interests is complete.

Date: 29/06/2020

Signature:

SIGNED